Clinical-trial enrollment is often described as a recruitment problem. By the time recruitment is visibly behind, however, the causes may reach back months: protocol burden, optimistic feasibility, site mix, startup delays, competition, geography, referral pathways, or data that arrived too late to change the plan.
AI cannot make those causes disappear. It can help a team detect patterns earlier, compare more evidence, and rehearse interventions before committing time and capital.
That is a valuable role—but a narrower and more defensible one than “AI solves enrollment.”
Enrollment is a changing system
A forecast created during feasibility begins aging immediately. Sites activate at different times. Screening behavior changes. Competing trials open. Eligibility assumptions meet actual patient populations. A static spreadsheet can appear precise while the operating system underneath it has moved.
Research on enrollment prediction has increasingly treated the problem as dynamic and data-rich. One study used data from 46,724 clinical trials to evaluate machine-learning approaches for predicting enrollment success. Another examined machine-learning approaches to clinical-trial site selection. These studies are signals of possibility, not universal performance guarantees: results depend on indication, trial design, data availability, geography, and the definition of success.
The strategic opportunity is to build a learning loop around enrollment rather than a one-time prediction.
Four places AI can help
1. Feasibility evidence synthesis
Teams can combine internal history, public trial records, epidemiology, investigator experience, claims or EHR-derived signals where appropriately licensed, and current competitive activity. AI can organize and compare that evidence, flag contradictions, and expose where the feasibility story rests on assumption rather than observation.
It should not erase data lineage. A site score without visible evidence is difficult to challenge and easy to over-trust.
2. Site portfolio design
The aim is not merely to rank individual sites. It is to build a resilient portfolio across startup time, patient access, investigator capacity, geography, competition, and operational risk.
Models can help identify combinations that look strong under different assumptions. Clinical operations leaders still decide which trade-offs are acceptable and which local realities the data does not capture.
3. Dynamic forecasting
Once activation and screening data begin to arrive, a forecast should update. The useful output is not a single date; it is a range of plausible trajectories, the assumptions driving them, and the signals most likely to change the outlook.
A forecast is decision support. It should help answer, “When must we act to preserve options?”—not merely, “What date does the model predict?”
4. Intervention rehearsal
AI-assisted scenario analysis can help teams compare actions: add sites, shift geography, improve referral support, revisit outreach, change operating cadence, or assess a protocol amendment through the appropriate governance path.
Scenario output is not causal proof. Opening two sites does not guarantee a particular number of patients. It gives leaders a structured way to examine dependencies, lead times, costs, and downside before deciding.
The data trap
More data does not automatically produce better site decisions.
Historical performance can encode selection bias. A prominent site may have strong records because it repeatedly received attractive trials. A community site may appear weak because it lacks recorded history, not patients. Indication labels may be too coarse. Referral networks can change. Data from one sponsor or CRO may not transfer cleanly to another.
Every model therefore needs questions around:
- representativeness across populations and geographies;
- missingness and measurement differences;
- the age of the evidence;
- leakage from post-selection information;
- fairness in site opportunity; and
- whether the proposed score is actually actionable.
The goal is not to replace investigator and field knowledge. It is to create a better argument between the data and that knowledge.
An illustrative decision room
Consider a hypothetical Phase 2 study whose enrollment forecast begins to soften six weeks after the first wave of activations.
The system does not declare which sites to close. It prepares a decision brief:
- activation and screening movement by site;
- differences from the original assumptions;
- protocol-related screen-failure patterns;
- current competing-trial changes;
- sites with leading indicators not yet visible in enrollment totals;
- three intervention scenarios with lead times, dependencies, and uncertainty; and
- the data missing from each conclusion.
Clinical, biostatistical, medical, and operational leaders review the same evidence and choose the response. The improvement is not autonomous trial management. It is a shorter distance from signal to accountable action.
Measure whether the system changes decisions
A strong enrollment capability should be evaluated on more than forecast error. Useful signals include:
- calibration of prediction ranges;
- time between a material signal and review;
- frequency of forecast refresh;
- false-positive interventions avoided;
- site-portfolio concentration and resilience;
- quality of source traceability; and
- whether decisions occurred early enough to preserve options.
Because enrollment is influenced by many concurrent factors, claims about months saved or cash preserved require careful causal evidence. Until that evidence exists, measure the operating mechanism honestly.
Keep the protocol and the patient in view
No analytics layer can compensate for an infeasible protocol, inaccessible visits, weak referral paths, or a poor patient experience. Enrollment is not merely a number generated by sites. It is the outcome of a system experienced by patients, caregivers, investigators, coordinators, and sponsors.
AI earns its place when it helps those people see the system earlier and act with better context. It fails when a score becomes a substitute for listening to them.